Drug intelligence / Profile preview

human histamine immunoglobulin

Development stage: Unknown
Lead developer: Grand Shuyang Life Sciences
Administration: Subcutaneous

Overview

**Human histamine immunoglobulin** is a plasma-derived human immunoglobulin preparation formulated with histamine phosphate and marketed by Grand Shuyang Life Sciences in China. It is approved for prevention and treatment of allergic diseases, including bronchial asthma, allergic skin diseases, and urticaria. The product is supplied as a 12 mg/vial preparation and is intended to induce anti-histamine antibodies that neutralize endogenous histamine and reduce histamine-mediated allergic responses.

Brand names: 蜀阳敏宁
Other names: Human Histaglobulin组织胺人免疫球蛋白

Beyond the preview

Go deeper on human histamine immunoglobulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on human histamine immunoglobulin.

Explore the full profile